---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-352233"
form_type: "8-K/A"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2026-08-14T20:10:15+00:00"
generated_at: "2026-08-14T20:18:00.938848+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma details COO Kling's exit: unvested equity canceled, $50k/mo advisor fee

## Summary
- Douglas Kling resigned as COO effective Aug 14, 2026, to become CEO of another clinical-stage biotech.
- Unvested stock options and RSUs canceled as of separation date, except those vesting on continued service through May 14, 2027.
- Kling entered Advisor Agreement with NewAmsterdam Pharma B.V. for $50,000/month plus expenses for PREVAIL trial and other clinical programs.
- Advisor Agreement runs to May 14, 2027; includes confidentiality, non-disparagement, non-solicitation covenants.

## SEC filing metadata
- accession: 0001193125-26-352233
- form_type: 8-K/A
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2026-08-14T20:10:15+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312526352233/0001193125-26-352233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312526352233/nams-20260716.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-352233
- JSON: https://secwatch.observer/filing/0001193125-26-352233.json
- Plain text: https://secwatch.observer/filing/0001193125-26-352233.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.